glp 1 drugs and anxiety Part 2 of a 3-Part Series; GLP-1 Medications for Weight Loss GLP-1 receptor agonists show promise

Cells 11 , 308 (2022)

Biol Reprod (2012) 86(6):174

The problem is that pricing pressures and patent expirations are expected to be significant headwinds for Novo Nordisk in the near term

Although several limitations exist in the analysis of the FAERS database, the preliminary findings in this work could provide a better basis for understanding the potential psychiatric AEs that may occur with GLP-1 RA treatment, assisting clinicians to focus on these AEs and provide early intervene for optimal risk management

For different GLP-1 RAs, the data limits during data retraction were coinciding with their respective first approval date (Table S3)